R63
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 7
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.170
- WNT_BETA_CATENIN_SIGNALING+0.170
- MYOGENESIS+0.130
- DNA_REPAIR+0.080
- APICAL_JUNCTION+0.050
- HEDGEHOG_SIGNALING+0.040
- MYC_TARGETS_V2+0.030
- APICAL_SURFACE+0.020
- KRAS_SIGNALING_DN+0.000
- PEROXISOME-0.010
Top 10 suppressed
- PROTEIN_SECRETION-0.580
- MYC_TARGETS_V1-0.430
- ANDROGEN_RESPONSE-0.410
- MTORC1_SIGNALING-0.370
- INTERFERON_ALPHA_RESPONSE-0.360
- UV_RESPONSE_DN-0.360
- INTERFERON_GAMMA_RESPONSE-0.350
- COMPLEMENT-0.330
- APOPTOSIS-0.310
- E2F_TARGETS-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG851 | — | — | 0.887 |
| 2 | SRR1404168 | GTEX | — | 0.884 |
| 3 | d2c9b21d-0f64-4182-9d5d-82b80a158a1f | — | — | 0.883 |
| 4 | SRR1797247 | — | cohortSC | 0.872 |
| 5 | MDT-AP-1160 | Med | Medulloblastoma | 0.870 |
| 6 | SRR1797238 | — | cohortSC | 0.863 |
| 7 | R129 | — | — | 0.861 |
| 8 | SRR1797231 | — | cohortSC | 0.858 |
| 9 | ea635e80-1225-4f52-a6cf-8f4c20201240 | — | — | 0.857 |
| 10 | df6cc1d8-c28f-4530-95ff-4e18ee383e88 | — | — | 0.857 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.170 | Inavolisib | — uncovered |
| MYOGENESIS | 0.130 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.080 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.050 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.040 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.030 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.020 | Temsirolimus | — uncovered |